Bp Consulting, Inc

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 2 drugs with upcoming expirations

Activity

Key Events

Aug 28, 2025FDALopressor — LOPRESSOR

Aug 28, 2025FDAKapspargo Sprinkle — LOPRESSOR

Apr 10, 2025FDALopressor — LOPRESSOR

Apr 10, 2025FDAKapspargo Sprinkle — LOPRESSOR

Dec 18, 2024FDARetrovir — RETROVIR

Nov 11, 2024FDARetrovir — RETROVIR

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

3 patent groups across drugs · Source: FDA Orange Book

DrugExpires

Zovirax2 patentsMar 23, 2027 ZoviraxJun 16, 2030 Lopressor2 patentsJul 9, 2035

Regulatory

Regulatory Timeline

20173 events

FDANov 28

Retrovir — RETROVIR

Application NDA019951

FDANov 28

Retrovir — RETROVIR

Application NDA019910

FDANov 28

Retrovir — RETROVIR

Application NDA019655

20185 events

FDASep 10

Retrovir — RETROVIR

Application NDA019910

FDASep 10

Retrovir — RETROVIR

Application NDA019655

FDASep 10

Retrovir — RETROVIR

Application NDA019951

FDAJan 26

Lopressor — KAPSPARGO SPRINKLE

Application NDA210428 (NDA)

FDAJan 26

Kapspargo Sprinkle — KAPSPARGO SPRINKLE

Application NDA210428 (NDA)

20191 event

FDAMar 29

Zovirax — AVACLYR

Application NDA202408 (NDA)

20203 events

FDAJun 18

Retrovir — RETROVIR

Application NDA019910

FDAJun 18

Retrovir — RETROVIR

Application NDA019951

FDAJun 18

Retrovir — RETROVIR

Application NDA019655

20244 events

FDADec 18

Retrovir — RETROVIR

Application NDA019910

FDADec 18

Retrovir — RETROVIR

Application NDA019655

FDANov 11

Retrovir — RETROVIR

Application NDA019951

FDANov 11

Retrovir — RETROVIR

Application NDA019951

20254 events

FDAAug 28

Lopressor — LOPRESSOR

Application NDA218698 (NDA)

FDAAug 28

Kapspargo Sprinkle — LOPRESSOR

Application NDA218698 (NDA)

FDAApr 10

Lopressor — LOPRESSOR

Application NDA219373 (NDA)

FDAApr 10

Kapspargo Sprinkle — LOPRESSOR

Application NDA219373 (NDA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)